Abcam PLC (NASDAQ:ABCZY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Abcam PLC (NASDAQ:ABCZY) traded down 4.394% during trading on Monday, reaching $14.035. The company had a trading volume of 717 shares. The company’s 50-day moving average is $13.96 and its 200 day moving average is $12.39. Abcam PLC has a 52 week low of $9.13 and a 52 week high of $14.68. The firm has a market capitalization of $2.84 billion and a price-to-earnings ratio of 54.824.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/11/abcam-plc-abczy-downgraded-by-zacks-investment-research.html.

Receive News & Stock Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related stocks with our FREE daily email newsletter.